Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...

Regina Toomey Bueno, former oncology admin at Garnet Health, had good insurance, lots of support, and 2 cancer diagnoses. She ...

March is Myeloma Awareness Month, a time to recognize the subtle but serious symptoms of multiple myeloma, including persistent fatigue, unexplained bone pain and anemia. Since diagnosis is often ...

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in ...

Dr. Joseph Mikhael discusses early signs, treatments and supportive care for multiple myeloma in an interview with CURE.

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

An elderly patient who was initially suspected of having antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) was instead diagnosed with multiple myeloma, according to a case report ...

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

A multiple myeloma treatment offers hope, but has a high cost. A Houston trial aims to make this life-saving therapy ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...